Related Experiment Video
Updated: Jun 17, 2026
05:45
Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing
Published on: October 25, 2019
Physiologic hyperleptinemia in obesity does not affect vasopressin secretion in acute hypo- or hyperosmolality
Minneke J Coenraad1, Marijke Frölich, A E Meinders
1Department of Internal Medicine, Leiden University Medical Center, 2300RC Leiden The Netherlands. m.j.coenraad@lumc.nl
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|December 17, 2009
Summary
Obese individuals do not show abnormal arginine vasopressin (AVP) secretion in response to hydration or salt challenges. Hormone leptin is not linked to AVP levels in normal or obese subjects.
Area of Science:
- Endocrinology
- Nephrology
- Metabolic Disorders
Background:
- Obesity is associated with impaired water excretion.
- The role of arginine vasopressin (AVP) and leptin in obesity-related water balance disturbances is unclear.
Purpose of the Study:
- To investigate AVP secretion in obese individuals under acute hypo- and hyperosmolar conditions.
- To determine if leptin influences AVP secretion in obesity.
Main Methods:
- Two tests were conducted: water load and intravenous hypertonic saline infusion.
- Ten normal-weight and ten obese females were studied, with obese subjects tested before and after weight loss.
Main Results:
- Obese subjects excreted less water load than controls, which improved after weight loss.
- Plasma AVP concentrations and responses to osmotic challenges were similar between obese and normal-weight women.
- No correlation was found between leptin and AVP levels.
Conclusions:
- AVP secretion is not different in obese versus normal-weight individuals under acute osmotic stress.
- Leptin does not appear to correlate with AVP in either group.
More Related Videos
Related Concept Videos
01:22Diabetes Insipidus II: Pathophysiology
Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:21Hyperosmolar Hyperglycemic State
Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:29Diabetes Insipidus I: Introduction
Definition Diabetes insipidus is a disorder marked by the production of large amounts of dilute urine because of impaired vasopressin production, release, or kidney response. The lack of effective vasopressin action limits water reabsorption in the renal collecting ducts, which leads to excessive urinary water loss and intense thirst.Clinical PresentationIndividuals with diabetes insipidus report persistent thirst and very high urine output. In severe cases, fluid intake can reach up to 20...